Paul Alan Sobotka

Paul Alan Sobotka
Academic background
EducationB.S., Chemistry
M.D.
Alma materLeland Stanford Junior University
University of Illinois College of Medicine, Chicago
Academic work
InstitutionsUniversity of Minnesota
Ohio State University

Paul Alan Sobotka is an American physician and academic. He is a professor at the University of Minnesota and Ohio State University.[1]

Sobotka's research has focused on autonomic and sympathetic nervous system–targeted, device-based therapies for resistant hypertension, heart failure, and related cardiorenal disorders. He is a fellow of the American College of Physicians and the American Heart Association.[2]

Education

Sobotka earned a Bachelor of Science in Chemistry from Leland Stanford Junior University in 1976, followed by a Doctor of Medicine degree from the University of Illinois College of Medicine, Chicago in 1980.[3]

Career

Sobotka began his academic career in 1983 as an instructor at Northwestern University Hospitals. In 1986, he was appointed assistant professor at Loyola University Medical Center, where he was promoted to associate professor in 1992. Between 1997 and 2002, he worked as a professor as well as vice chairman of the Department of Medicine at Wayne State University School of Medicine. Since 2007, he has been a professor of medicine at the University of Minnesota, and since 2008, he has also held a professorship in medicine at Ohio State University.[1]

Sobotka has also held several administrative and professional appointments throughout his career. Additionally, from 2007 to 2014, he was associate director at the Berman Institute for Outcomes and Clinical Research at Hennepin County Medical Center.[1] Moreover, he was also appointed as the entrepreneur in residence in the White House between 2012 and 2013.[4]

Research

Sobotka's research has centered on cardiovascular physiology and innovative diagnostic and therapeutic treatments for hypertension and congestion. Throughout his career, he has been involved in clinical research on endovascular and interventional therapies aimed at improving blood pressure control in patients with treatment-resistant hypertension.[5] He has conducted clinical studies of renal sympathetic denervation, a minimally invasive catheter-based procedure that targets renal nerve pathways to achieve sustained reductions in blood pressure in patients unresponsive to conventional pharmacologic therapy.[6] He also participated in long-term follow-up data from the Symplicity HTN-1 trial and reported durable blood pressure reductions over several years, highlighting the potential of this approach in selected patient populations.[7]

In addition to working on renal denervation, Sobotka has contributed to interdisciplinary research on vascular and haemodynamic interventions[8] and their implications for cardiovascular[9] and systemic health.[10] His work also spans broader discussions of hypertension management, including commentary on renal denervation's potential role in heart failure and related conditions.[11] Additionally, beyond clinical trials and procedural innovation, his work has integrated insights from invasive[12] and non-invasive diagnostic methods to better understand how autonomic nerve activity and vascular properties contribute to disease progression and treatment response.[13]

Awards and honors

Selected articles

  • Krum, H., Schlaich, M., Whitbourn, R., Sobotka, P. A., Sadowski, J., Bartus, K., ... & Esler, M. (2009). Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. The Lancet, 373(9671), 1275–1281.
  • Costanzo, M. R., Guglin, M. E., Saltzberg, M. T., Jessup, M. L., Bart, B. A., Teerlink, J. R., ... & UNLOAD Trial Investigators. (2007). Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. Journal of the American College of Cardiology, 49(6), 675–683.
  • Schlaich, M. P., Sobotka, P. A., Krum, H., Lambert, E., & Esler, M. D. (2009). Renal sympathetic-nerve ablation for uncontrolled hypertension. New England Journal of Medicine, 361(9), 932–934.
  • Symplicity HTN-2 Investigators. (2010). Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. The Lancet, 376(9756), 1903–1909.
  • Mahfoud, F., Schlaich, M., Kindermann, I., Ukena, C., Cremers, B., Brandt, M. C., ... & Böhm, M. (2011). Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation, 123(18), 1940–1946.

References

  1. 1 2 3 "CV - Academia.edu".
  2. 1 2 3 4 "Paul A Sobotka MD FA - Doximity".
  3. ↑ "Paul A. Sobotka - U.S. News".
  4. ↑ "V-Flow Medical - Y Combinator".
  5. ↑ Azizi, Michel; Schmieder, Roland E.; Mahfoud, Felix; Weber, Michael A.; Daemen, Joost; Davies, Justin; Basile, Jan; Kirtane, Ajay J.; Wang, Yale; Lobo, Melvin D.; Saxena, Manish; Feyz, Lida; Rader, Florian; Lurz, Philipp; Sayer, Jeremy; Sapoval, Marc; Levy, Terry; Sanghvi, Kintur; Abraham, Josephine; Sharp, Andrew S. P.; Fisher, Naomi D. L.; Bloch, Michael J.; Reeve-Stoffer, Helen; Coleman, Leslie; Mullin, Christopher; Mauri, Laura (9 June 2018). "Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial". Lancet. 391 (10137): 2335–2345. doi:10.1016/S0140-6736(18)31082-1. ISSN 1474-547X. PMID 29803590.
  6. ↑ Shen, Mark J.; Zipes, Douglas P. (14 March 2014). "Role of the autonomic nervous system in modulating cardiac arrhythmias". Circulation Research. 114 (6): 1012. doi:10.1161/CIRCRESAHA.113.302549. ISSN 1524-4571. PMID 24625726.
  7. ↑ Grassi, Guido; Mark, Allyn; Esler, Murray (13 March 2015). "The sympathetic nervous system alterations in human hypertension". Circulation Research. 116 (6): 986. doi:10.1161/CIRCRESAHA.116.303604. ISSN 1524-4571. PMC 4367954. PMID 25767284.
  8. ↑ Mahfoud, Felix; Böhm, Michael; Schmieder, Roland; Narkiewicz, Krzysztof; Ewen, Sebastian; Ruilope, Luis; Schlaich, Markus; Williams, Bryan; Fahy, Martin; Mancia, Giuseppe (1 November 2019). "Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry". European Heart Journal. 40 (42): 3480. doi:10.1093/eurheartj/ehz118. ISSN 1522-9645. PMC 6837160. PMID 30907413.
  9. ↑ Xu, Bo; Zheng, Hong; Liu, Xuefei; Patel, Kaushik P. (1 May 2015). "Activation of afferent renal nerves modulates RVLM-projecting PVN neurons". American Journal of Physiology. Heart and Circulatory Physiology. 308 (9): H1103–1111. doi:10.1152/ajpheart.00862.2014. ISSN 1522-1539. PMC 4551125. PMID 25637549.
  10. ↑ Thorp, Alicia A.; Schlaich, Markus P. (2015). "Relevance of Sympathetic Nervous System Activation in Obesity and Metabolic Syndrome". Journal of Diabetes Research. 2015 341583. doi:10.1155/2015/341583. ISSN 2314-6753. PMC 4430650. PMID 26064978.
  11. ↑ Steinberg, Jonathan S.; Blount, Nicholas; Ponomarev, Dmitry; Shabanov, Vitaly; Pokushalov, Evgeny; Romanov, Alexander (19 May 2023). "The Evaluate Renal Artery Denervation in Addition to Catheter Ablation to Eliminate Atrial Fibrillation (ERADICATE-AF) trial: arrhythmia suppression, blood pressure control, and potential interactions". Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology: Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology. 25 (5) euad107. doi:10.1093/europace/euad107. ISSN 1532-2092. PMC 10228602. PMID 37084084.
  12. ↑ Mahfoud, Felix; Schlaich, Markus; Kindermann, Ingrid; Ukena, Christian; Cremers, Bodo; Brandt, Mathias C.; Hoppe, Uta C.; Vonend, Oliver; Rump, Lars C.; Sobotka, Paul A.; Krum, Henry; Esler, Murray; Böhm, Michael (10 May 2011). "Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study". Circulation. 123 (18): 1944. doi:10.1161/CIRCULATIONAHA.110.991869. ISSN 1524-4539. PMID 21518978.
  13. ↑ Mahfoud, Felix; Böhm, Michael; Schmieder, Roland; Narkiewicz, Krzysztof; Ewen, Sebastian; Ruilope, Luis; Schlaich, Markus; Williams, Bryan; Fahy, Martin; Mancia, Giuseppe (1 November 2019). "Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry". European Heart Journal. 40 (42): 3474–3482. doi:10.1093/eurheartj/ehz118. ISSN 1522-9645. PMC 6837160. PMID 30907413.
  14. ↑ "Lloyd W. Dinkelspiel Awards".
This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.